ACR 3.08% 6.3¢ acrux limited

The forecast Evamist numbers have been reachedActually, Evamist...

  1. 1,539 Posts.
    lightbulb Created with Sketch. 5
    The forecast Evamist numbers have been reached

    Actually, Evamist sales are running at about 5% of expected peak, so far, which is not very good more than a year after the product's launch. Evamist has been a serious disappointment, so far.

    I stand by my argument that its breadth of products makes Acrux a better defensive investment than most biotechs, but quite a bit now hinges on Axiron.
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.